Table 3.
Number of carriers of BRCA1 or BRCA2 PVs included in the study by testing ascertainment center and BGP and non-BGP cohort.
| Testing-Ascertainment Center | All Carriers | Carriers of BRCA1 PVs (%) | Carriers of BRCA2 PVs (%) |
|---|---|---|---|
| Cogentech-IEO | 353 | 195 (55.2) | 158 (44.8) |
| Cogentech-INT | 309 | 187 (60.5) | 122 (39.5) |
| Cogentech-OPG * | 90 | 53 (58.9) | 38 (41.1) |
| Cogentech-ICH | 61 | 39 (63.9) | 22 (36.1) |
| ACSS * | 206 | 107 (51.9) | 100 (48.1) |
| All cohorts | 1019 * | 581 (57.0) | 440 (43.0) |
| BGP | 100 | 59 (59.0) | 41 (41.0) |
| non-BGP * | 919 | 522 (56.8) | 399 (43.2) |
| All | 1019 * | 581 (57.0) | 440 (43.0) |
* Of the 1019 carriers, one from OPG and one from ACSS (both from non-BGP) carried each a PV in BRCA1 and a PV in BRCA2.